Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion type Assertion NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_head.
- NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion description "[In addition to hydroxyurea, second line cytotoxic chemotherapy agents and hematopoietic cell transplant have been used for aggressive forms of HES and CEL with outcomes reported for limited numbers of patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_provenance.
- NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion evidence source_evidence_literature NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_provenance.
- NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion SIO_000772 21761433 NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_provenance.
- NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion wasDerivedFrom befree-20150227 NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_provenance.
- NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_assertion wasGeneratedBy ECO_0000203 NP310318.RAkmi-F_q_fHNIoiBnvU5KjNLg-LB4HOATenctcMRQWbQ130_provenance.